Retrospective analyses of BRAF V600R-mutated metastatic melanoma propose a response to BRAFi monotherapy in 27 to 83% and to BRAFi plus MEKi combination therapy in 55% of cases with a significant benefit for PFS (3.8 vs. 8.0 months) and OS (7.3 vs. 22.9 months) with the combination therapy when compared to BRAFi monotherapy [13••, 21]. The gene discussed is BRAF; the disease is metastatic melanoma.